OQROSign up free
Politician trade (House)

Pfizer (PFE): Rep. Julie Johnson (TX32) disclosed a partial sale $1K–$15K

Rep. Julie Johnson (TX32) disclosed a partial sale of Pfizer in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
28 days
Disclosure lag
Traded
Jan 15, 2025
Disclosed
Feb 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 21, 2024CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  2. Dec 20, 2024FDAFDA drug approval: Braftovi
  3. Dec 20, 2024Layoff notice · Heights Union East, 2002 N. 6th Floor, TAMPA, FL, 33602Layoff notice filed in FL: 62 employees
  4. Jan 15, 2025 · this disclosureCongressDisclosed partial sale of PFE — reported range $1,001 - $15,000

What came next

  1. Jan 24, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  2. Jan 31, 2025FDAFDA drug approval: Paxlovid (Copackaged)
  3. Feb 12, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  4. Feb 13, 2025InsiderDirector purchased ~$499K of PFE shares in the open market
  5. Feb 13, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  6. Feb 21, 2025FDAFDA drug approval: Xeljanz
  7. Feb 21, 2025FDAFDA drug approval: Xeljanz XR
  8. Feb 24, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  9. Feb 25, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  10. Feb 26, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  11. Mar 3, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  12. Mar 4, 2025InsiderOfficer sold ~$65K of PFE shares in the open market
  13. Mar 10, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  14. Mar 12, 2025FDAFDA drug approval: Mektovi
  15. Mar 12, 2025FDAFDA drug approval: Braftovi
  16. Mar 31, 2025Congress · 1 personMembers of Congress: 2 sales
  17. Apr 8, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  18. Apr 11, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  19. Apr 21, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  20. Apr 23, 2025FDAFDA drug approval: Ibrance
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Pfizer

OQRO holds no insider, Congress, fund or contract record for Pfizer dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Rep. Julie Johnson (TX32)

The full history of Rep. Julie Johnson (TX32) is on the profile page.

How this filing works

Explore the data

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data